PubMed Health⌕ Search

Biomedical subjects

Barbara Mroczko

Publications and source records attributed to Barbara Mroczko.

34 records · Page 2Linked to original sources
PubMed2004

[Plasma level of macrophage-colony stimulating factor (M-CSF) in the course of breast cancer treatment].

Macrophage-colony stimulating factor (M-CSF) is one of the glycoproteins called colony-stimulating factors (CSF). Some clinical investigations have shown an autologous production of M-CSF in various human cell lines in vitro and by tumour cells in vivo. We have investigated the plasma level of M-CSF and commonly accepted tumour marker, such as CA 15-3 in the plasma of 44 patients with breast cancer. Blood was taken before and in 30 and 180 days after surgery. The patients were divided into two groups: A (stage 1) and B (stage 11). M-CSF was determined using enzyme-linked immunosorbent assay (ELISA), CA 15-3 was measured by microparticle enzyme immunoassay (MEIA). M-CSF plasma levels were significantly higher in breast cancer patients before and after surgery comparing to the control group. The M-CSF level was higher in group B (11 stage) compared to the group A (I stage). These results suggest the potential role of M-CSF in the diagnostics and monitoring of breast cancer chemotherapy.

Adult↗
PubMed2003

Hematopoietic growth factors in colorectal cancer patients.

Hematopoietic growth factors (HGFs) are involved in the regulation of growth and spread of cancer. Therefore, in the present study, we have investigated in colorectal cancer patients the serum levels of selected HGFs, such as stem cell factor (SCF), interleukin 3 (IL-3), granulocyte-macrophage-colony stimulating factor (GM-CSF), and M-CSF in relation to controls and to the classical tumor markers, such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) in colorectal cancer. Additionally, we have compared the serum levels of cytokines with tumor site and stage and other clinical characteristics such as age and sex. We also defined the receiver-operating characteristics (ROC) curve for HGFs and classical tumor markers. The tested cytokines were measured in 70 patients with colorectal cancer and in 40 healthy subjects. HGFs were determined using enzyme-linked immunosorbent assay (ELISA). CEA and CA 19-9 were measured by microparticle enzyme immunoassay. There were significant differences in the levels of circulating SCF, IL-3, M-CSF, GM-CSF, and CEA and CA 19-9 in the colorectal cancer patients compared to the control group. The levels of M-CSF and CEA were significantly higher in patients with a more advanced tumor stage. The significant positive correlation was observed between the CEA and CA 19-9 concentrations. The M-CSF serum levels correlated positively with the tested tumor markers. The M-CSF area under the ROC curve was the largest. These results suggest that M-CSF is, among the tested HGFs, the best candidate for a colorectal cancer tumor marker.

Adult↗
PubMed2003

Diagnostic value of pancreatic elastase-1 in human acute pancreatitis.

The diagnosis of acute pancreatitis (AP) is usually confirmed by a significant increase of the serum amylase and/or lipase level. However, serum pancreatic elastase-1 (pEla-1) was found to be a more sensitive diagnostic marker in AP, when assayed by the radioimmunoassay procedure. We analyzed the serum concentration of pEla-1, measured by the ELISA technique in 46 patients with AP and in a control group of 12 healthy volunteers. On admission (day 1) we found significantly higher pEla-1 levels in patients with AP than in the controls. During the following days, the concentration of pEla-1 rapidly decreased to nearly undetectable values on the 3rd day. There was no significant difference between patients with mild and severe AP nor those of different etiology. We suggest that pEla-1 has little diagnostic value and does not provide additional information to that of the less expensive and more widely available serum amylase and lipase.

Acute Disease↗
PubMed2003

[Macrophage colony-stimulating factor (M-CSF) as a candidate for the tumor marker of breast cancer].

Macrophage--colony stimulating factor (M-CSF) is one of the glycoproteins called colony-stimulating factors (CSFs). Some clinical investigations have shown autologous production of M-CSF various human cell lines in vitro and by tumors in vivo. We have investigated the plasma level of M-CSF and commonly accepted tumour markers, such as CA 15-3 in breast cancer. The plasma levels of cytokines were measured in 30. patients with breast cancer before surgery and 20. healthy subjects. The patients were divided into two groups: A (stage I) and B (stage II). M-CSF was determined using enzyme-linked immunosorbent assay (ELISA), CA 15-3 was measured by microparticle enzyme immunoassay (MEIA). Mean M-CSF and CA 15-3 plasma levels were significantly higher in breast cancer patients compared to the control group. The M-CSF level was significantly higher (statistical significance) in group B (II stage) when compared to group A (I stage) and group B to control group. The diagnostic sensitivity of M-CSF were related to the stage of disease (group A--10%, group B--40%) and combined use with CA 15-3 (group A--30%, group B--65%). These results suggest a potential role for M-CSF as tumour marker for breast cancer.

Adult↗
PubMed2003

[Cytokines as tumor markers in breast cancer].

Serum tumour markers may be helpful in early diagnosis of breast cancer, in the initial assessment of the extent of the disease, and in monitoring of the tumor growth or tumor volume reduction. Recent studies have focused the role of cytokines as a new group of tumour markers for breast cancer.

Biomarkers, Tumor↗
PubMed2003

[Selected hematopoietic cytokines in patients with colorectal cancer].

We have investigated the serum level of selected hematopoietic cytokines, such as interleukin 3, granulocyte-macrophage--colony stimulating factor (GM-CSF), granulocyte--colony stimulating factor (G-CSF) and macrophage--colony stimulating factor (M-CSF) in colorectal cancer patients. Also correlations between their concentrations and stages were made. The study was done on group consisted of 30 diagnosed colorectal cancer patients. The used classification of stage of the tumor was described by Dukes. The results were compared with control group consisted of 20 healthy persons. The examined factors were assayed by ELISA method. In colorectal cancer patients the serum levels of IL-3, GM-CSF and M-CSF were increased in comparison with the control group. The differences between cytokines concentrations in control group and colorectal cancer patients were statistically significant for GM-CSF and M-CSF. The serum levels of cytokines were higher in more advanced tumor stage. This results permit for further study on usefulness of these cytokines as a markers for colorectal cancer.

Adult↗
PubMed2003

[Stem cell factor (SCF) in clinical practice].

Stem cell factor (SCF) is a hematopoietic factor active in the early stages of hematopoiesis. Recognition of biological properties of SCF made a hope for its use in diagnosis and therapy of many diseases, especially neoplasmas. We present a characterization of SCF, its attempts to use in medicine and future possibilities of application. We describe also possibilities for clinical use of soluble receptor (s-kit) and inhibitors of SCF.

Biomarkers, Tumor↗
PubMed2002

Granulocyte-colony stimulating factor (G-CSF) and macrophagecolony stimulating factor (M-CSF) in colorectal cancer patients.

We have investigated the serum level of granulocytecolony stimulating factor (G-CSF) and macrophagecolony stimulating factor (M-CSF) and the commonly accepted tumor markers, such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) in colorectal cancer. Additionally, we have defined the diagnostic sensitivity, specificity, positive predictive value, negative predictive value and receiver-operating characteristics (ROC) curve for G-CSF and M-CSF. The serum levels of cytokines were measured in 49 patients with colorectal cancer and in 40 healthy subjects. G-CSF and M-CSF were determined using enzyme-linked immunosorbent assay (ELISA). CEA and CA 19-9 were measured by microparticle enzyme immunoassay. There were significant increases in the level of circulating G-CSF and M-CSF in the colorectal cancer patients compared to the control group. Moreover, the diagnostic sensitivity of M-CSF was higher (65%) than the sensitivity of CEA (31%) and CA 19-9 (20%). The diagnostic specificities of M-CSF and G-CSF were 95%, and the M-CSF predictive value was higher compared with the predictive value of G-CSF. These results suggest a potential role for M-CSF as a tumor marker for colorectal cancer.

Adult↗
PubMed2002

[Tumor markers useful for diagnosis and monitoring of lung neoplasm].

Serum tumour markers may be helpful in early diagnosis of lung cancer, in the initial assessment of the extent of the disease, and in monitoring of the tumour growth or tumour volume reduction, once cancer has been diagnosed and treatment started. Recent studies have focused especially--cytokines as a new group of tumour markers.

Antigens, Neoplasm↗
PubMed2002

[Proinflammatory cytokines (IL-6, TNF-alpha) and cardiac troponin I (cTnI) in serum of young people with ventricular arrhythmias].

UNLABELLED: In the most cases the origin of ventricular arrhythmias is ischaemic, necrosis focus or presence of the connective tissue in cardiac muscle. The aim of the study was to evaluate troponin I (cTnI), interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) vs in young subject with ventricular arrhythmias. Into the study group included young people without organic heart diseases, dyselectrolitemia, with normal ECG which has not elevated levels of C-reactive protein (55 persons). The control group consisted of 22 healthy persons. The values of cTnI were not increased. The TNF-alpha concentrations were elevated in persons with ventricular arrhythmias (92 +/- 232 pg/mL vs. 2 +/- 1 pg/mL, p < 0.001). The IL-6 concentrations were slightly elevated without statistical significance (1.5 +/- 4.5 pg/mL i 0.1 +/- 0.04 pg/mL, p = 0.06). CONCLUSIONS: There was no evidence of myocardial injury in young people with ventricular arrhythmias (cTnI). We noted increase levels of proinflammatory cytokines. It might suggest that the background of ventricular arrhythmias is inflammation.

Adolescent↗
PubMed2002

[Neoplasm markers useful for diagnosis and monitoring of colonic neoplasms].

Serum tumor markers: CEA, CA 19-9, AFP, TPS may be helpful in early diagnosis of colorectal cancer, in the initial assessment of the extent of the disease, and in monitoring of the tumor growth or tumor volume reduction once cancer has been diagnosed and treatment started. Recent studies have focused on a new substances (candidates for tumour markers) of colorectal cancer.

Antigens, Neoplasm↗
PubMedDate not supplied

Serum concentrations of MCP-1 and RANTES in patients during aortic surgery: the relationship with ischemia-reperfusion.

INTRODUCTION: Surgical trauma is associated with depression of the immune system, which results in a high complication rate following abdominal aortic aneurysm (AAA) repair. Monocyte chemotactic protein-1 (MCP-1) and regulated-on-activation normal T cell expressed and secreted (RANTES) protein are important mediators of the immune and inflammatory response. The aim of this study was to determine whether there is any relationship between MCP-1 or RANTES and operative injury and ischemia-reperfusion during AAA surgery in human. MATERIAL AND METHODS: Peripheral blood samples were taken from 12 patients before surgery, after anesthesia induction, before unclamping of aorta (PreXoff), 90 min after unclamping (90 minXoff), and at 24 and 48 h after surgery. RESULTS: The MCP-1 and RANTES serum concentrations were measured with the ELISA technique. MCP-1 concentration significantly increased after reperfusion (90 minXoff) in comparison with the PreXoff level (p=0.001). Twenty-four hours after AAA repair, MCP-1 significantly decreased 269-225 pg/ml (p=0.005) and reached preoperative value. RANTES level was higher in AAA patients before surgery than in controls (p=0.025) and decreased significantly after ischemia-reperfusion to 13 ng/ml (p< 0.001) at 90 minXoff. We showed increases in RANTES concentration to 26 ng/ml on the 1st and to 31 ng/ml on the 2nd day after surgery (p=0.020, p=0.012, respectively) compared with the 90 min Xoff level. CONCLUSIONS: Ischemia-reperfusion during AAA repair results in an increase in MCP-1 and decrease in RANTES concentrations in serum. The changes in chemokine concentrations may influence the development of immunosuppression after AAA repair, contributing to the postoperative course.

Adult↗